Halozyme (HALO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sean Laaman from Morgan Stanley maintained a Buy rating on the stock and has a $73.00 price target.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Sean Laaman has given his Buy rating due to a combination of factors that highlight Halozyme’s strong financial performance and strategic initiatives. The company has raised its 2025 financial guidance, reflecting confidence in increased royalty revenues, API sales, and partner orders. This upward revision in guidance suggests an expectation of earnings per share outperformance, driven by cost discipline and robust revenue streams.
Additionally, Halozyme’s ENHANZE business remains a significant growth driver, with ongoing litigation not anticipated to impact its operations. The company’s strategic moves, such as a $250 million share repurchase program and exploration of M&A opportunities in the drug-delivery space, further demonstrate a commitment to enhancing shareholder value. These factors, combined with limited tariff exposure and recent milestone achievements, contribute to the positive outlook for Halozyme in the current market environment.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $79.00 price target.